Schuurmans takes over from Jan Dekker. He held senior executive positions at Biocartis and MyCartis, and prior to Cergentis, he lead Skyline Dx' melanoma programme.

In addition, the Cergentis Supervisory Board will be strengthened with Dirk Pollet, CEO of Enzyre, and Maja Sanders. She currently holds supervisory roles at various (non-)profit organisations and has built up extensive managerial experience in the private equity industry.

Jan Groen, Chairman of the Board commented: "A heartfelt gratitude to outgoing CEO Jan Dekker, who laid the foundation for Cergentis to take the next step to accelerate the development and commercialisation of its unique TLA technology for cancer diagnostics. We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also very pleased with the appointment of our new Board members Maja and Dirk."

Cergentis develops and commercialises kits and services based on its proprietary Targeted Locus Amplification (TLA) technology.